COPD Inhibitors
Chemical inhibitors of COPD can disrupt its role in intracellular trafficking by influencing the assembly or function of coatomer complexes or the formation of vesicles at the endoplasmic reticulum or Golgi apparatus. Brefeldin A, for instance, is known to inhibit the formation of the coatomer complex by interfering with the activation of ADP-ribosylation factors, essential for vesicle formation, thus it can hinder the function of COPD in the coatomer complex. Similarly, Golgicide A targets Golgi brefeldin A resistant guanine nucleotide exchange factor 1 (GBF1), which is crucial for the maintenance of Golgi structure and function; its inhibition can affect coatomer complex assembly and thus COPD function. Cytochalasin D and Latrunculin A, which disrupt the actin cytoskeleton, can prevent the proper movement of vesicles, indirectly affecting COPD's role in trafficking. Neomycin binds to phosphoinositides, which are essential for vesicle formation, and its binding can interfere with COPD's role in vesicle formation at the Golgi.
Furthermore, chemicals such as Nocodazole and Vinblastine, which interfere with microtubule polymerization, can disrupt the microtubule-dependent transport of vesicles, thereby indirectly inhibiting COPD's function. Colchicine, another microtubule inhibitor, also disrupts microtubule dynamics, which is essential for vesicle movement along the cytoskeleton. Monensin, by altering the pH within the Golgi apparatus, can disrupt protein transport and processing, indirectly affecting COPD's role in the secretion pathway. Tunicamycin inhibits N-linked glycosylation, which can lead to misfolded proteins and thus disrupt the protein transport mechanism in which COPD is involved. Chlorpromazine, which interferes with clathrin coat assembly, can also impact vesicle formation, potentially affecting COPD's role in vesicular trafficking. Lithium chloride's impact on inositol phosphatase and subsequent phosphoinositide metabolism can also alter membrane trafficking pathways, thereby affecting COPD's function.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts protein transport by inhibiting the formation of the coatomer complex, potentially inhibiting COPD function as part of this complex. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Destabilizes microtubules, which could disrupt vesicular traffic and indirectly inhibit COPD function in transport processes. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Inhibits actin polymerization, which could affect vesicle movement and indirectly inhibit the function of COPD in intracellular trafficking. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Disrupts Golgi function by altering pH, which could indirectly inhibit the function of COPD in vesicular transport. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Inhibits N-linked glycosylation, potentially disrupting the function of COPD by affecting protein folding and transport. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Inhibitor of dynamin, which could indirectly inhibit COPD by disrupting vesicle scission from the Golgi. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Specifically inhibits Golgi brefeldin A resistant guanine nucleotide exchange factor 1 (GBF1), which may indirectly inhibit COPD by disrupting coatomer function. | ||||||
Neomycin sulfate | 1405-10-3 | sc-3573 sc-3573A | 1 g 5 g | $27.00 $35.00 | 20 | |
Aminoglycoside that disrupts phosphoinositide signaling, which could affect vesicle formation and indirectly inhibit COPD function. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $61.00 $110.00 | 21 | |
Interferes with clathrin assembly, which might indirectly inhibit COPD by affecting vesicle formation and trafficking. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Binds to tubulin, potentially disrupting microtubule-dependent processes, including those involving COPD. | ||||||